We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+25.85%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.06B
AUM Growth
+$329M
Cap. Flow
-$217M
Cap. Flow %
-5.35%
Top 10 Hldgs %
37.39%
Holding
124
New
4
Increased
35
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$40.6M
2
GPCR icon
Structure Therapeutics
GPCR
+$16.4M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.8M
4
BPMC
Blueprint Medicines
BPMC
+$12.7M
5
IMVT icon
Immunovant
IMVT
+$12.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$84.9M
2
HUM icon
Humana
HUM
+$62.4M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.6M
4
ABCM
Abcam PLC
ABCM
+$28.9M
5
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.98%
2 Consumer Staples 1.41%
3 Industrials 1.03%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$266M 6.54%
2,881,567
+196,273
+7% +$12.7M
IMCR icon
2
Immunocore
IMCR
$1.72B
$182M 4.48%
2,661,507
-282,203
-10% -$14.7M
KRTX
3
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$163M 4.01%
515,024
+9,591
+2% +$1.86M
NBIX icon
4
Neurocrine Biosciences
NBIX
$16.8B
$158M 3.88%
1,196,000
-40,000
-3% -$4.6M
HUM icon
5
Humana
HUM
$43.7B
$142M 3.49%
310,000
-126,500
-29% -$62.4M
PEN icon
6
Penumbra
PEN
$12.7B
$135M 3.33%
537,500
+33,750
+7% +$7.46M
EVH icon
7
Evolent Health
EVH
$348M
$131M 3.22%
3,960,000
+95,000
+2% +$2.69M
UNH icon
8
UnitedHealth
UNH
$376B
$121M 2.98%
230,000
– –
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$113M 2.79%
2,674,245
+145,129
+6% +$4.17M
AGL icon
10
Agilon Health
AGL
$1.53B
$108M 2.67%
345,200
+13,500
+4% +$4.89M
ISRG icon
11
Intuitive Surgical
ISRG
$127B
$101M 2.48%
298,500
– –
IDXX icon
12
Idexx Laboratories
IDXX
$44.1B
$99.5M 2.45%
179,250
-15,250
-8% -$7.16M
PODD icon
13
Insulet
PODD
$11.5B
$93.7M 2.31%
431,750
+51,750
+14% +$8.88M
ARGX icon
14
argenx
ARGX
$53.4B
$87.2M 2.15%
229,250
-29,750
-11% -$13.9M
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.45B
$83.9M 2.06%
1,754,038
+277,597
+19% +$10.8M
ACHC icon
16
Acadia Healthcare
ACHC
$2.76B
$83.5M 2.05%
1,073,500
+165,500
+18% +$12.3M
EXAS
17
DELISTED
Exact Sciences
EXAS
$75.4M 1.86%
1,019,500
+1,250
+0.1% +$81.9K
DXCM icon
18
DexCom
DXCM
$31.5B
$74M 1.82%
596,000
+12,000
+2% +$1.23M
BSX icon
19
Boston Scientific
BSX
$69.5B
$71.3M 1.75%
1,232,500
+72,500
+6% +$3.87M
RYTM icon
20
Rhythm Pharmaceuticals
RYTM
$6.81B
$70M 1.72%
1,522,893
-74,230
-5% -$2.34M
ALGN icon
21
Align Technology
ALGN
$12.1B
$60.3M 1.48%
220,000
+3,000
+1% +$711K
XENE icon
22
Xenon Pharmaceuticals
XENE
$6.06B
$57.8M 1.42%
1,255,577
+77,575
+7% +$2.74M
FRPT icon
23
Freshpet
FRPT
$2.93B
$57.5M 1.42%
662,500
– –
MIRM icon
24
Mirum Pharmaceuticals
MIRM
$6.46B
$54.7M 1.35%
1,851,464
+30,731
+2% +$930K
PHR icon
25
Phreesia
PHR
$663M
$51.1M 1.26%
2,206,700
+430,309
+24% +$7.42M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Rock Springs Capital Management held 124 positions worth $4.06B, up 8.8% from $3.73B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Rock Springs Capital Management withdrew a net $217M in Q4 2023, closing 20 positions and reducing 29 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $84.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Eli Lilly worth $40.5M.

  • Rock Springs Capital Management's largest Q4 2023 buy was Eli Lilly: 69,500 shares worth $40.5M.
  • Rock Springs Capital Management added most to Celldex Therapeutics in Q4 2023, an estimated $13.8M increase.
  • Rock Springs Capital Management's biggest Q4 2023 reduction was Humana, cutting an estimated $62.4M.
  • Rock Springs Capital Management fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $84.9M.
  • Rock Springs Capital Management's ten largest holdings make up 37% of its $4.06B portfolio in Q4 2023.
  • Rock Springs Capital Management opened 4 new positions and closed 20 in Q4 2023.
  • Rock Springs Capital Management's portfolio value rose 8.8% quarter-over-quarter to $4.06B.

Based on Rock Springs Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.